Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fox Corp Class A (FOXA) vs Merck & Co., Inc. (MRK) Price & Performance

Fox Corp Class ATrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Fox Corp Class A vs Merck & Co., Inc. — how do they compare? Fox Corp Class A trades at $62.43 (market cap $25.05B), while Merck & Co., Inc. trades at $130.23 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 12.9× Fox Corp Class A's market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.

FOXAMRK
Market Cap
$25.05B$323.00B
Sector
MediaHealth
52-Week High
$76.11$131.84
52-Week Low
$48.79$77.60
Enterprise Value
$28.41B$369.77B
Dividend Yield
0.91%2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fox Corp Class A

FOXA trades at $64.03, up 3.63% on strong Q4 2026 earnings beats driven by World Cup advertising and Tubi streaming growth. The stock shows bullish technical momentum with a consensus price target of $65.33, supported by a 50% buy rating from analysts. Revenue grew to $16.30B in 2025, with net income margin expanding to 13.88%, though 2026 projections indicate moderation.

Outlook remains positive with digital ad momentum and strategic initiatives, but risks include sports cost pressures and cyclical advertising dependence. The current valuation at a P/E of 16.52 appears reasonable relative to earnings growth, offering potential upside if execution continues.

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Fox Corp Class A

Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.

Read more on FOXA

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK